Lynestrenol 1 mg.-mestranol 0.1 mg: a new low dose oral contraceptive: a clinical study
Kamal, I.; Hefnawi, F.; Younis, N.
Egyptian Population and Family Planning Review 3(1): 11-15
1970
ISSN/ISBN: 1110-1156 PMID: 12254506 Document Number: 479189
39 women (23 from the family planning clinic at Cairo University Hospital and 16 private patients) who took 1 mg lynestrenol + .1 mg mestranol were followed on therapy for 6-12 months, the total number of cycles being 336. The women took the tablet for 22 days starting from the fifth cycle day of the first cycle and then refrained from therapy for 6 days. Average cycle lengths were 30.3 days and 28.1 days for the hospital and private groups, respectively. Average flow lengths were 3.6 and 3.39 days, respectively. Flow was moderate, slight, and severe in 67.2, 27.8%, and 2.9% of the cycles, respectively. 8 amenorrheic cycles and 17 cycles with spotting or bleeding occurred. 70% of the cycles had complaints of dysmenorrhea. Headaches occurred in 34.8% and 15% of the hospital and private group cycles, respectively. Increase in the incidence of fall of hair occurred in 11.8% of the total number of cycles. The average increase in weight was 2.1 kg/year. No significant changes in blood pressure occurred nor did any thromboembolic manifestations. No suspicious or malignant smears occurred. Pregnancy protection was total. Almost all participants reported subjective impro vement of symptoms experienced with higher dose pills.